Key Points
- Benjamin Hindson sold 8,283 shares on November 24 at an average price of $19.00 for about $157,377, reducing his stake by 1.88% to 432,605 shares (≈$8.22M).
- Shares trade near $19 with a market cap of $2.41B and a one‑year range of $6.78–$20.34; the company posted Q3 EPS of -$0.22 (beat -$0.27) on $149M revenue but remains unprofitable with negative margins and ROE.
- Institutional ownership is high (84.68%) after large stake increases by UBS AM, Millennium, AQR and Wellington, while analyst coverage is mixed with a consensus "Hold" and an average target of $14.88.
10x Genomics (NASDAQ:TXG - Get Free Report) insider Benjamin Hindson sold 8,283 shares of the firm's stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $157,377.00. Following the completion of the transaction, the insider owned 432,605 shares in the company, valued at approximately $8,219,495. This trade represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
10x Genomics Stock Performance
Shares of NASDAQ:TXG opened at $19.07 on Wednesday. The stock has a 50-day simple moving average of $13.67 and a 200-day simple moving average of $12.52. The stock has a market capitalization of $2.41 billion, a P/E ratio of -30.76 and a beta of 2.13. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $20.34.
10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The firm had revenue of $149.00 million for the quarter, compared to analyst estimates of $142.50 million. During the same quarter last year, the firm posted ($0.30) earnings per share. 10x Genomics's revenue for the quarter was down 1.7% compared to the same quarter last year. 10x Genomics has set its Q4 2025 guidance at EPS. Analysts predict that 10x Genomics will post -1.43 earnings per share for the current year.
Institutional Trading of 10x Genomics
Hedge funds and other institutional investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of 10x Genomics by 235.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock worth $62,016,000 after acquiring an additional 4,987,195 shares in the last quarter. Millennium Management LLC raised its position in shares of 10x Genomics by 434.5% in the 1st quarter. Millennium Management LLC now owns 5,377,492 shares of the company's stock valued at $46,946,000 after purchasing an additional 4,371,327 shares in the last quarter. AQR Capital Management LLC raised its position in shares of 10x Genomics by 241.3% in the 2nd quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company's stock valued at $47,916,000 after purchasing an additional 2,925,372 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of 10x Genomics by 126.6% during the 3rd quarter. Wellington Management Group LLP now owns 4,285,628 shares of the company's stock valued at $50,099,000 after buying an additional 2,394,355 shares during the last quarter. Finally, Quantinno Capital Management LP grew its position in shares of 10x Genomics by 207.2% during the second quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company's stock worth $25,864,000 after buying an additional 1,506,530 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
TXG has been the topic of several recent research reports. Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a report on Monday, November 17th. Wall Street Zen cut 10x Genomics from a "buy" rating to a "hold" rating in a research note on Saturday, November 15th. Barclays upped their target price on 10x Genomics from $15.00 to $17.00 and gave the stock an "overweight" rating in a research report on Friday, November 7th. Morgan Stanley dropped their target price on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Tuesday, August 12th. Finally, Zacks Research lowered 10x Genomics from a "strong-buy" rating to a "hold" rating in a research report on Monday, November 10th. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $14.88.
Read Our Latest Analysis on TXG
About 10x Genomics
(
Get Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
